bêta
IA Trial Radar
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus Phase I 37 Premier chez l'homme Randomisé Double aveugle Contrôlé par placebo

Terminé
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT01835730 était conçu pour étudier le traitement de Diabète Sucré de Type 2 (T2DM). Il s'agissait d'une étude interventionnel en Phase I. Son statut actuel est : terminé. L'étude a commencé le 1 avril 2013, avec un objectif de recruter 37 participants. Dirigée par PhaseBio Pharmaceuticals Inc., l'étude s'est terminée le 1 mai 2014. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 15 octobre 2014.
Résumé succinct
This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).
Titre officiel

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Pathologies
Diabète Sucré de Type 2 (T2DM)
Autres identifiants de l'étude
  • PE0139-PT-CL-0001
Numéro NCT
NCT01835730
Date de début (réel)
2013-04
Dernière mise à jour publiée
2014-10-15
Date de fin (estimée)
2014-05
Inscription (estimée)
37
Type d'étude
Interventionnel
PHASE
Phase I
Statut
Terminé
Objectif principal
Traitement
Méthode d'allocation
Randomisé
Modèle d'intervention
Groupe unique
Masquage
Quadruple aveugle
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalPE0139 Injection
Single subcutaneous injection of PE0139, 40 mg/mL
PE0139 Injection
Comparateur placeboPlacebo
Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
PLACEBO
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Change in Vital Signs from baseline (Day 0 Pre-dose)
Safety will be evaluated by analyses of the change from baseline in vital signs.
Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28
Change in ECGs from baseline (Day -1)
Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.
ECG Days 2 and 28
Change in Safety Labs from baseline (Pre-dose)
Safety will be evaluated by analyses of the safety laboratory parameters.
Safety Labs Days 0, 7 and 28
Incidence and severity of immunogenicity
Safety will be evaluated by the incidence and severity of immunogenicity.
Immunogenicity Days 0, 7, 14 and 28
Incidence and severity of adverse events including hypoglycemia
Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.
As reported between Days -10 to 28
Critère secondaire d'évaluation
Critères d'évaluationDescription de la mesurePériode
Pharmacokinetic Profile
Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)
Day 0, 1, 2, 3, 4, 5, 6, and 7
Pharmacodynamic Response
To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).
FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
  • Willing and able to sign a written informed consent and follow all study-related procedures;
  • Male and female subjects at least 18 years of age;
  • Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their dose of study drug;
  • Body mass index ≤45 kg/m2;
  • Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months prior to screening.

  • Currently taking or have taken within 3 months prior to screening an approved or investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide;
  • Currently taking or have routinely taken, within 3 months prior to screening , a short-acting insulin;
  • Currently taking or have taken, within 3 months prior to screening, a long acting insulin other than Lantus®;
  • Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components;
  • Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes during the study period;
  • History of recurrent severe hypoglycemia (more than 2 episodes within the last 6 months prior to randomization or hypoglycemic unawareness;
  • Malignant disease defined as 1) any history of malignant melanoma or breast cancer and/or 2) history of other types of cancer within the last 5 years prior to screening;
  • Unstable cardiovascular disease defined as one or more of the following: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; History of or currently have New York Heart Association Class III-IV heart failure prior to screening; Uncontrolled/sustained hypertension; History or evidence of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT interval;
  • Clinically significant renal and/or hepatic dysfunction;
  • Absolute requirement for corticosteroids or have received systemic steroids within 3 months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical corticosteroids will be permitted;
  • Pregnant or lactating female subjects;
  • Known history of or active alcohol abuse or use of illicit drugs within 1 year prior to screening;
  • Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at V1;
  • Participating in any other study and have received any other investigational medication or device within 30 days prior to Visit 1.
  • Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk.
PhaseBio Pharmaceuticals Inc. logoPhaseBio Pharmaceuticals Inc.
Aucune donnée de contact disponible
3 Centres de l'étude dans 1 pays

Alabama

Pinnacle Research Group, LLC, Anniston, Alabama, 36207, United States

Florida

Palm Springs Research Institute, Hialeah, Florida, 33012, United States

Washington

Rainier Clinical Research, Renton, Washington, 98057, United States